Results for &quot;&quot;Lapatinib&quot;&quot;[mesh_terms]

A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.

R S Midgley, D J Kerr, K T Flaherty, J P Stevenson, S E Pratap, K M Koch, D A Smith, M Versola, R A Fleming, C Ward, P J O'Dwyer, M R Middleton

Annals of oncology : official journal of the European Society for Medical Oncology 2008;18(12):2025-9

Effects of food on the relative bioavailability of lapatinib in cancer patients.

Kevin M Koch, Nandi J Reddy, Roger B Cohen, Nancy L Lewis, Bonnie Whitehead, Kathleen Mackay, Andrew Stead, Andrew P Beelen, Lionel D Lewis

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(8):1191-6

EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.

Torsten Trowe, Sotiria Boukouvala, Keith Calkins, Richard E Cutler, Ryan Fong, Roel Funke, Steven B Gendreau, Yong D Kim, Nicole Miller, John R Woolfrey, Valentina Vysotskaia, Jing Ping Yang, Mary E Gerritsen, David J Matthews, Peter Lamb, Timothy S Heuer

Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(8):2465-75

Identification of an Oxidative Stress-Related LncRNA Signature for Predicting Prognosis and Chemotherapy in Patients With Hepatocellular Carcinoma.

Zixuan Zhong, Minxuan Xu, Jun Tan

Pathology oncology research : POR 2022;28():1610670

Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors.

Wandena S Siegel-Lakhai, Jos H Beijnen, Walter L Vervenne, Henk Boot, Marianne Keessen, Melissa Versola, Kevin M Koch, Deborah A Smith, Lini Pandite, Dirk J Richel, Jan H M Schellens

Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(15 Pt 1):4495-502

Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies.

Quincy S C Chu, Garry Schwartz, Johann de Bono, Deborah A Smith, Kevin M Koch, Melissa J Versola, Lini Pandite, Nikita Arya, Jan Curtright, Ronald A Fleming, Peter T C Ho, Eric K Rowinsky

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(24):3753-8

Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours.

Lot A Devriese, Kevin M Koch, Marja Mergui-Roelvink, Gemma M Matthys, Wen Wee Ma, Andre Robidoux, Joe J Stephenson, Quincy S C Chu, Keith W Orford, Leanne Cartee, Jeff Botbyl, Nikita Arya, Jan H M Schellens

Investigational new drugs 2015;32(3):481-8

EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma.

Yassine Lalami, Pol M Specenier, Ahmad Awada, Denis Lacombe, Cecilia Liberatoscioli, Catherine Fortpied, Iman El-Hariry, Jan Bogaerts, Guy Andry, J A Langendijk, Jan B Vermorken

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2013;105(2):238-40

Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.

Matteo Simonelli, Paolo A Zucali, Elena Lorenzi, Luca Rubino, Fabio De Vincenzo, Rita De Sanctis, Matteo Perrino, Luca Mancini, Luca Di Tommaso, Lorenza Rimassa, Giovanna Masci, Monica Zuradelli, Matteo B Suter, Monica Bertossi, Giuseppe Fattuzzo, Laura Giordano, Massimo G Roncalli, Armando Santoro

European journal of cancer (Oxford, England : 1990) 2013;49(5):989-98

The Molecular Mechanisms of Regulating Oxidative Stress-Induced Ferroptosis and Therapeutic Strategy in Tumors.

Jinghan Zhu, Yixiao Xiong, Yuxin Zhang, Jingyuan Wen, Ning Cai, Kun Cheng, Huifang Liang, Wanguang Zhang

Oxidative medicine and cellular longevity 2021;2020():8810785

Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer.

Arlene Chan, Catherine Shannon, Richard de Boer, Sally Baron-Hay, Andrew Redfern, Astrid Bauwens, Paul Craft, Suzanne Webb, Amanda Townsend, Dusan Kotasek

Asia-Pacific journal of clinical oncology 2015;10(4):368-75

Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.

Alberto Zambelli, Matteo Giovanni Della Porta, Ermanno Eleuteri, Luciana De Giuli, Oronzo Catalano, Carlo Tondini, Alberto Riccardi

Breast (Edinburgh, Scotland) 2011;20(2):176-83

A water-based mechanism of specificity and resistance for lapatinib with ErbB family kinases.

Robert C Rizzo, Yulin Huang

Biochemistry 2012;51(12):2390-406

A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA).

Joachim Bischoff, Jana Barinoff, Christoph Mundhenke, Dirk O Bauerschlag, Serban-Dan Costa, Daniel Herr, Kristina Lübbe, Frederik Marmé, Nicolai Maass, Gunter von Minckwitz, Eva-Maria Grischke, Volkmar Müller, Marcus Schmidt, Bernd Gerber, Sherko Kümmel, Claudia Schumacher, Petra Krabisch, Sabine Seiler, Marc Thill, Valentina Nekljudova, Sibylle Loibl

Anti-cancer drugs 2020;30(4):394-401